TuHURA Biosciences Extends Cash Runway to Late 2028, Secures $50M Credit Facility & Begins ATM Sales
HURA has more than doubled off its 52-week low of $0.41.
Summary
TuHURA Biosciences reported Q1 2026 results, extending its cash runway to late 2028 through a new $50M credit facility and initial ATM sales, mitigating prior going concern concerns.
Key Events · Financing and Capital Events · HURA
-
Cash Runway Extended
The company expects its existing capital resources, including the new $50 million revolving credit facility, to fund planned operations into the end of 2028. This significantly extends the runway and addresses the prior going concern warning issued on March 31, 2026.
-
Q1 2026 Financial Results
TuHURA Biosciences reported a net loss of $7.5 million for the three months ended March 31, 2026, compared to a $6.7 million net loss in Q1 2025. Cash and cash equivalents were $6.3 million as of March 31, 2026.
-
ATM Program Initiated
The company began making sales under its At-The-Market (ATM) offering program in April 2026, selling 104,000 shares at a weighted average price of $3.09 per share for gross proceeds of $321,000. The program allows for sales of up to $50 million in common stock.
-
$50 Million Credit Facility Details
The $50 million revolving credit facility from Parkview Holdings One LLC (an affiliate of a >5% stockholder) bears 12% interest. A $5 million commitment fee was paid by issuing 1,878,287 shares of common stock (subject to stockholder approval). No proceeds have been drawn from the facility to date.
Analysis · HURA · Life Sciences
This quarterly report provides a critical update on TuHURA Biosciences' financial stability, extending its cash runway into late 2028. This directly addresses the previous going concern warning by detailing the impact of the recently secured $50 million revolving credit facility and initial sales under the $50 million At-The-Market (ATM) program. While the company continues to incur losses and faces significant potential dilution from warrants and future equity issuances, the successful securing of long-term funding is a major de-risking event for its operations and clinical trials.
At the time of this filing, HURA was trading at $2.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $147.1M. The 52-week trading range was $0.41 to $4.05. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.